NasdaqHealth CareHealth Care SuppliesS&P SmallCap 600
$87.23
-2.39 (-2.67%)
Close of Nov 06, 2026 · end-of-day data
MMSI 8-K filings, explained
Every material Form 8-K Merit Medical Systems has filed with the SEC since December 19, 2024, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Merit Medical reported third-quarter 2026 revenue of $416.2 million, up 8.4% from a year earlier, and GAAP EPS of $0.70, up 51%. The company raised its full-year 2026 revenue and non-GAAP EPS guidance, and separately disclosed a $45 million cash acquisition of Solo Pace, Inc.
Q3 2026 reported revenue $416.2 million, up 8.4%; organic constant currency revenue up 9%
GAAP gross margin fell to 48.2% from 48.5%; GAAP operating margin rose to 14.1% from 11.1%
Full-year 2026 non-GAAP EPS guidance raised to $4.33-$4.37 from $4.25-$4.35; revenue guidance to $1.635-$1.642 billion from $1.631-$1.643 billion
Solo Pace acquisition completed October 13, 2026 for cash of approximately $45 million
Merit Medical said it eliminated its Chief Operating Officer position in an August 14, 2026 reorganization and named Sheri Lewis Executive Vice President of Global Operations, effective August 31, 2026. Neil W. Peterson, the former COO, became Senior Advisor and has given notice of resignation for good reason effective March 5, 2027. The filing describes a leadership change in the operations function without any reported financial results.
Sheri Lewis appointed EVP of Global Operations effective August 31, 2026, with a $600,000 base salary and $400,000 signing bonus
Lewis's target annual bonus is 60% of base salary, with a maximum of 200%
Neil W. Peterson's COO title was changed to Senior Advisor; his resignation takes effect March 5, 2027
Lewis's agreement provides a lump sum of two times salary plus bonus average if terminated without cause or for good reason after a change of control
Merit Medical reported second-quarter 2026 revenue of $418.8 million, up 10% from a year earlier, and GAAP diluted EPS of $0.65, up from $0.54. The company raised its full-year 2026 revenue guidance to $1.631 billion to $1.643 billion and its non-GAAP EPS guidance to $4.25 to $4.35, both above its April 30, 2026 outlook. Year-to-date operating cash flow and free cash flow both declined, at $110.0 million (down 11%) and $76.6 million (down 14%).
Q2 2026 reported revenue $418.8 million, up 10%; constant currency organic revenue up 9%
GAAP EPS $0.65 vs. $0.54 a year earlier; non-GAAP EPS $1.19, up 18%
2026 revenue guidance raised to $1.631-$1.643 billion; non-GAAP EPS guidance raised to $4.25-$4.35 from $4.01-$4.15
Year-to-date cash flow from operations $110.0 million, down 11%; free cash flow $76.6 million, down 14%
At its annual meeting on May 13, 2026, Merit Medical shareholders approved the 2026 Equity Incentive Plan and the 2026 Employee Stock Purchase Plan, elected four directors, and ratified Deloitte and Touche LLP as auditor for fiscal 2026. The Board also adopted Fifth Amended and Restated Bylaws effective May 14, 2026. The equity plan reserves a maximum of 2,700,000 shares of common stock for awards, which shareholders should weigh when considering future share issuance.
Equity Incentive Plan approved with 48,750,003 votes for and 1,510,844 against; maximum share reserve of 2,700,000 shares
Four directors elected: Martha G. Aronson, Lonny J. Carpenter and Scott R. Ward to 2029 terms; Lynne N. Ward to a 2027 term
Say-on-pay advisory vote passed with 48,835,995 for and 1,415,355 against
Fifth A&R Bylaws, effective May 14, 2026, add remote meeting participation, electronic notice and updated universal proxy provisions
Merit Medical reported first-quarter 2026 revenue of $381.9 million, up 7%, and non-GAAP earnings per share of $0.94, up 9%. The company raised its full-year 2026 revenue forecast slightly and kept its non-GAAP earnings per share forecast unchanged, after accounting for the April 1, 2026 acquisition of View Point Medical, which is expected to dilute 2026 non-GAAP earnings per share by about $0.05.
Q1 2026 revenue was $381.9 million, up 7% from $355.4 million a year earlier; constant currency organic growth was 2.7%, or 3.7% excluding the divested DualCap product line.
GAAP diluted EPS was $0.68 versus $0.49 a year earlier; non-GAAP EPS was $0.94 versus $0.86.
2026 revenue guidance is $1.612 billion to $1.634 billion, up from $1.610 billion to $1.630 billion; non-GAAP EPS guidance is unchanged at $4.01 to $4.15.
The View Point Medical acquisition closed April 1, 2026 for $140 million, of which $90 million was paid in cash at closing.
Merit Medical reported fourth-quarter 2025 revenue of $393.9 million, up 11%, and non-GAAP EPS of $1.04, up 12%. For fiscal 2026 it guided to total revenue of $1.610 billion to $1.630 billion and non-GAAP EPS of $4.01 to $4.15, implying growth of 6% to 8% and 5% to 8%, respectively.
Q4 2025 GAAP EPS was $0.63, up from $0.46 a year earlier; non-GAAP EPS was $1.04 versus $0.93.
Full-year 2025 revenue was $1.516 billion, up 12%, and non-GAAP EPS was $3.83, up 11%.
2026 guidance: revenue of $1.610 billion to $1.630 billion and non-GAAP EPS of $4.01 to $4.15, excluding possible effects of trade policies and unannounced acquisitions.
Merit Medical said preliminary, unaudited fourth-quarter 2025 revenue was in the range of $389 million to $395 million, up about 10% to 11% from a year earlier, or 8% to 10% in constant currency. The company also named F. Ann Millner as Board Chair after founder Fred P. Lampropoulos resigned as director and Chair, which matters to shareholders because the company's leadership is changing while full 2025 results and 2026 guidance are still pending.
Preliminary Q4 2025 revenue of about $389 million to $395 million, up about 10% to 11% year over year; constant currency growth of about 8% to 10%
Lampropoulos resigned as director and Chair effective January 4, 2026, citing personal reasons, and is not leaving over any dispute or financial reporting matter
F. Ann Millner, formerly Lead Independent Director, became Chair effective January 5, 2026; the board also reduced its size from eleven to ten members
Full 2025 results and fiscal 2026 guidance are scheduled for release after the close on February 24, 2026
Merit Medical reported third-quarter 2025 revenue of $384.2 million, up 13.0%, and non-GAAP EPS of $0.92, up 6.7%, while GAAP EPS fell 3.0% to $0.46. The company raised its full-year 2025 net sales guidance to $1.502 to $1.515 billion and its non-GAAP EPS guidance to $3.66 to $3.79, and it said Martha G. Aronson has joined as President and CEO.
Q3 2025 revenue was $384.2 million, up 13.0% from $339.8 million a year earlier; constant currency revenue, organic, rose 7.8%
GAAP net income was $27.8 million, or $0.46 per diluted share, versus $28.4 million, or $0.48, in Q3 2024; non-GAAP EPS was $0.92 versus $0.86
Full-year 2025 net sales guidance rose to $1.502 to $1.515 billion from $1.495 to $1.507 billion; non-GAAP EPS guidance rose to $3.66 to $3.79 from $3.52 to $3.72
Martha G. Aronson is quoted as President and CEO, with the company referring to a transition from current leadership
Merit Medical Systems appointed Martha G. Aronson as President and CEO effective October 3, 2025, succeeding Fred P. Lampropoulos, who remains Chairman of the Board. The board also expanded its size from ten to eleven directors and added Ms. Aronson to the board, a leadership change that matters to shareholders as it sets a new chief executive direction.
Martha G. Aronson becomes President and CEO and a director effective October 3, 2025.
Fred P. Lampropoulos resigned as CEO and will serve as Executive Chairman until January 3, 2026, then remain a director and Chairman.
Ms. Aronson's offer letter includes a $1,000,000 base salary, a $250,000 signing bonus, and a target bonus of 100% of base salary.
Her initial equity award has a target grant date fair value of $5,500,000, and an upfront equity grant of $4,125,000 is planned.
Merit Medical reported second-quarter 2025 revenue of $382.5 million, up 13.2% from a year earlier, and raised its full-year 2025 net sales and non-GAAP earnings per share guidance. GAAP earnings per share fell to $0.54 from $0.61, while non-GAAP earnings per share rose to $1.01 from $0.92. The company also named Martha Aronson as its new President and Chief Executive Officer, effective October 3, 2025.
Q2 2025 net sales were $382.5 million, up 13.2%; constant currency revenue, organic, rose 6.7%
2025 net sales guidance raised to $1.495 billion to $1.507 billion from $1.480 billion to $1.501 billion
2025 non-GAAP EPS guidance raised to $3.52 to $3.72 from $3.28 to $3.41
Martha Aronson named President and CEO, effective October 3, 2025
Merit Medical said on July 7, 2025 that Martha Aronson will become President and CEO effective October 3, 2025, succeeding Fred Lampropoulos, who will remain Chairman. The company also reported preliminary, unaudited second-quarter revenue of approximately $380 million to $384 million, up about 12% to 14% from the prior-year quarter, with constant currency growth of about 11% to 13%. The revenue figures are not audited and may change when full results are released on July 30, 2025.
Martha Aronson to succeed Fred Lampropoulos as CEO effective October 3, 2025; Lampropoulos remains Chairman
Aronson offer includes a $1,000,000 base salary, a $250,000 signing bonus and a target annual bonus of 100% of salary
Initial equity award with a target grant-date fair value of $5,500,000, plus a $4,125,000 award on commencement of employment
Preliminary Q2 revenue of approximately $380 million to $384 million versus $338.0 million a year earlier; full results due after market close July 30, 2025
Merit Medical completed its merger with Biolife on May 20, 2025, paying about $120 million in cash on hand, and updated its 2025 guidance to include the business. Net sales guidance was raised to $1.480 billion to $1.501 billion from $1.470 billion to $1.490 billion, while the non-GAAP earnings per share range moved to $3.28 to $3.41 from $3.29 to $3.42. Management said the deal will be slightly dilutive to 2025 non-GAAP profitability.
Purchase price of about $120 million, subject to standard adjustments, paid with available cash; merger effective May 20, 2025
Biolife projected to contribute $10 million to $11 million of revenue from May 20 to December 31, 2025, after about $15 million in revenue for the twelve months ended December 31, 2024
2025 net sales guidance raised to $1.480 billion to $1.501 billion; non-GAAP EPS guidance $3.28 to $3.41 versus prior $3.29 to $3.42
About $7.2 million of non-cash and non-recurring transaction expenses excluded from non-GAAP projections; deal projected to be dilutive to 2025 GAAP net income and EPS
Merit Medical reported first-quarter 2025 revenue of $355.4 million, up 9.8%, and non-GAAP EPS of $0.86, up 14.8%. It kept its 2025 net sales guidance unchanged but lowered its 2025 non-GAAP EPS guidance, citing the projected impact of recently implemented trade policies, which matters to shareholders because it reduces expected full-year earnings even as first-quarter results beat expectations.
Q1 2025 net sales of $355.4 million, up 9.8% from $323.5 million a year earlier; GAAP net income of $30.1 million, or $0.49 per diluted share, versus $0.48 a year earlier
Non-GAAP EPS of $0.86 in Q1 2025, versus $0.75 in Q1 2024
2025 non-GAAP EPS guidance lowered to $3.29 to $3.42 from $3.58 to $3.70, citing trade policies
2025 net sales guidance reaffirmed at $1.470 billion to $1.490 billion
Merit Medical reported fourth-quarter and full-year 2024 results on February 25, 2025, with revenue up 9.4% in the quarter and 7.9% for the year. The company also issued 2025 guidance calling for revenue of $1.470 billion to $1.490 billion and non-GAAP earnings per share of $3.58 to $3.70, up 8% to 10% and 4% to 7% from 2024. GAAP earnings per share in the quarter slipped to $0.46 from $0.47 a year earlier.
Q4 2024 revenue was $355.2 million, up 9.4%; GAAP net income was $27.9 million, or $0.46 per diluted share, versus $0.47 a year earlier
Q4 2024 non-GAAP EPS was $0.93, up 25.8% from the prior year period
Full-year 2024 revenue was $1.357 billion, up 7.9%; GAAP EPS was $2.03 versus $1.62 in 2023
2025 guidance: revenue of $1.470 billion to $1.490 billion and non-GAAP EPS of $3.58 to $3.70
Merit Medical said preliminary unaudited revenue for the year ended December 31, 2024 is about $1.355 billion to $1.357 billion, up about 7.7% to 7.9% from the prior year. The figures are unaudited and may change after the audit, and the company plans to report full fourth-quarter and 2024 results and 2025 guidance on February 25, 2025.
Preliminary 2024 revenue of about $1.355 billion to $1.357 billion, up about 7.7% to 7.9% year over year
Preliminary constant currency revenue increased about 8.4% to 8.6%; the foreign exchange impact is $7.9 million
Audited results are not yet available, and the auditor has not reviewed the preliminary figures
Full 2024 results and fiscal 2025 guidance are scheduled for February 25, 2025 after market close
Merit Medical President Joseph Wright resigned effective January 3, 2025, after the company received allegations about his conduct that its independent directors investigated with outside counsel. The company says the allegations were unrelated to its operations or financial performance, and CEO Fred Lampropoulos was re-appointed as President.
Joseph C. Wright resigned on December 16, 2024, effective January 3, 2025, under a Separation Agreement and Release of All Claims.
Wright will forfeit stock options and performance stock units other than vested options and eligible PSUs as of the resignation date.
Fred P. Lampropoulos, age 75, the company's CEO since 1987, was re-appointed President; the filing states his compensation has not changed.
The filing says the allegations were unrelated to Merit's operations or financial performance; Lampropoulos is Wright's brother-in-law.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Merit Medical Systems filing is on SEC EDGAR ↗. 8-K briefs of other companies →